JPS6231720B2 - - Google Patents
Info
- Publication number
- JPS6231720B2 JPS6231720B2 JP51049756A JP4975676A JPS6231720B2 JP S6231720 B2 JPS6231720 B2 JP S6231720B2 JP 51049756 A JP51049756 A JP 51049756A JP 4975676 A JP4975676 A JP 4975676A JP S6231720 B2 JPS6231720 B2 JP S6231720B2
- Authority
- JP
- Japan
- Prior art keywords
- pertussis
- antigen
- protective
- denaturing agent
- bordetella pertussis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000427 antigen Substances 0.000 claims description 26
- 102000036639 antigens Human genes 0.000 claims description 26
- 108091007433 antigens Proteins 0.000 claims description 26
- 241000588832 Bordetella pertussis Species 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 101710194807 Protective antigen Proteins 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 229940066827 pertussis vaccine Drugs 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims 2
- 238000000034 method Methods 0.000 description 25
- 201000005702 Pertussis Diseases 0.000 description 20
- 230000001681 protective effect Effects 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 238000000605 extraction Methods 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 11
- 239000004202 carbamide Substances 0.000 description 11
- 239000002054 inoculum Substances 0.000 description 9
- 239000000284 extract Substances 0.000 description 8
- 239000003463 adsorbent Substances 0.000 description 7
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 239000003607 modifier Substances 0.000 description 5
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000007900 aqueous suspension Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003398 denaturant Substances 0.000 description 3
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 3
- 229960001340 histamine Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000003916 acid precipitation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 229960004198 guanidine Drugs 0.000 description 2
- 229960000789 guanidine hydrochloride Drugs 0.000 description 2
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 229910017119 AlPO Inorganic materials 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- -1 NaCl or KCl Chemical class 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002156 adsorbate Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000002357 guanidines Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4975676A JPS52134018A (en) | 1976-04-30 | 1976-04-30 | Antigen for protecting pertussis and vacczne containing same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4975676A JPS52134018A (en) | 1976-04-30 | 1976-04-30 | Antigen for protecting pertussis and vacczne containing same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS52134018A JPS52134018A (en) | 1977-11-09 |
JPS6231720B2 true JPS6231720B2 (ru) | 1987-07-09 |
Family
ID=12840021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4975676A Granted JPS52134018A (en) | 1976-04-30 | 1976-04-30 | Antigen for protecting pertussis and vacczne containing same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS52134018A (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5835121A (ja) * | 1981-08-20 | 1983-03-01 | ビラス・ヴィー・リクハイト | 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3395219A (en) * | 1964-12-11 | 1968-07-30 | Merck & Co Inc | Process for production of pertussis antigen |
US3405218A (en) * | 1965-09-22 | 1968-10-08 | Parke Davis & Co | Extracting bordetella pertussis antigens with lithium bromide |
-
1976
- 1976-04-30 JP JP4975676A patent/JPS52134018A/ja active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3395219A (en) * | 1964-12-11 | 1968-07-30 | Merck & Co Inc | Process for production of pertussis antigen |
US3405218A (en) * | 1965-09-22 | 1968-10-08 | Parke Davis & Co | Extracting bordetella pertussis antigens with lithium bromide |
Also Published As
Publication number | Publication date |
---|---|
JPS52134018A (en) | 1977-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1142083A (en) | Process for the isolation of membrane proteins from neisseria meningitidis and vaccines containing same | |
US4220717A (en) | Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b. | |
JPS6222970B2 (ru) | ||
US4271147A (en) | Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same | |
CA1181691A (en) | Vaccinal complex containing a specific antigen and vaccine containing it | |
DE68928432T2 (de) | Legionellosis-impfstoffe und verfahren zur herstellung | |
JPS59175440A (ja) | グラム陰性バクテリアのワクチン | |
HU185404B (en) | Process for preparing pertussis toxoide | |
AU2367500A (en) | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions | |
JP2549225B2 (ja) | 百日咳菌外膜蛋白質の精製方法 | |
EP0220387B1 (de) | Konjugatimpfstoffe gegen Infektionen durch gramnegative Bakterien, Verfahren zu deren Herstellung sowie Verwendung derselben | |
US4196192A (en) | Combined Haemophilus influenzae type b and pertussis vaccine | |
US4007265A (en) | Method for treating tetanus toxin with a proteinase to produce an atoxic immunogenic product | |
JPS625922A (ja) | 百日咳毒素の非毒素免疫原性調製剤の調製法と百日咳菌ワクチンの製造法 | |
JPH08785B2 (ja) | トレポネマ・ハイオジセンテリアエのバクテリン | |
EP0374178B1 (en) | Process for preparing veterinary acellular vaccines against gram-negative nonenteric pathogenic bacilli | |
FR2510606A1 (fr) | Procede d'obtention de polyosides capsulaires, polyosides capsulaires ainsi obtenus et leur application a la preparation de vaccins | |
JPH0834742B2 (ja) | 百日せき内毒素の除去法,百日せきトキソイドおよびその製造法 | |
JPS6231720B2 (ru) | ||
EP0090660A2 (en) | Neisseria gonorrhoeae vaccine | |
IL165970A (en) | Method of isolating biologically active fraction containing clinically acceptable native s-lipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides | |
CA1117866A (en) | Haemophilus influenzae vaccine | |
JP2634545B2 (ja) | Rtxトキシンファミリーに属する細菌毒素ワクチンの製造法 | |
US3968202A (en) | Tetanus antigen and process for its manufacture | |
RU2148412C1 (ru) | Способ получения протективного коклюшного антигена |